Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy
Wolfgang Miesbach/LinkedIn
Jul 9, 2026, 19:00

Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a proud post on Linkedin:

“Gene therapy in haemophilia has moved into a new phase—and ISTH 2026 reflects that. In the Gene Therapy oral session (OC 21.1–21.5), the focus clearly shifts toward durability, safety, and clinical impact after a single infusion.

Long‑term FVIII expression in haemophilia A:

OC 21.1 – GS1191‑0445 (AAV8‑FVIII) in severe haemophilia A (W. Liu, R. Yang, Y. Hu and colleagues):

Across three studies, lower‑dose AAV8‑FVIII gene therapy shows sustained FVIII activity and >97–99% reductions in annualized bleeding rates in the 3×10¹² and 4×10¹² vg/kg cohorts, with most treatment‑emergent events limited to grade 1–2 transaminase elevations and no FVIII inhibitors or thrombotic events.

Durable FIX expression in haemophilia B:

OC 21.2 – Dalnacogene ponparvovec (BBM‑H901) pooled phase II/III data in China (F. Xue, R. Yang, L. Zhang and co‑authors):

A single AAV‑Padua FIX infusion yields mean FIX levels in the mild/near‑normal range at 104 weeks, ABR ~0.5 in year 1, 84% of patients with zero treated bleeds over 2 years, disappearance of target joints, and no drug‑related serious AEs, inhibitors, thrombosis or tumors—underlining how Chinese centres are shaping the global evidence base for haemophilia B gene therapy.

OC 21.4 – 5‑year post hoc end‑of‑study analysis of etranacogene dezaparvovec in HOPE‑B (C. Hermans, W. Miesbach, S. Pipe and colleagues):

In responders, endogenous FIX activity remains stably around the 36–39 IU/dL range up to year 5, with adjusted ABRs markedly reduced versus lead‑in prophylaxis and ~98% reduction in exogenous FIX use, without late hepatotoxicity, oncogenicity or serious treatment‑related events.

Liver safety and immune‑mediated injury:

OC 21.5 – Histopathology of immune‑mediated hepatocellular injury after valoctogene roxaparvovec (V. La Mura, F. Peyvandi and team):

Real‑world cases with ALT elevation and loss of transgene expression show biopsy‑proven, immune‑mediated hepatitis with smooth ER changes and cytotoxic T‑cell predominance; personalized prednisone schedules help normalize ALT and preserve transgene expression, illustrating how liver biopsy can guide targeted immunosuppression.”

Wolfgang Miesbach: ISTH 2026 Showcases the Future of Gene Therapy

Stay updated with Hemostasis Today.

C. Hermans F. Peyvandi F. Xue Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today L. Zhang Medicine R. Yang S. Pipe V. La Mura W. Miesbach Wolfgang Miesbach
NewsFeed